Message

• 

• We would like to express our sincere gratitude for your continued support.
  In 2025, the Japanese economy continued to face uncertainty due to factors such as increased tariff-related costs for external demand, geopolitical instability, and rising prices driven by the depreciation of the yen. Under these circumstances, CellSeed worked to improve its financial position and strengthen a stable management foundation while advancing both its Regenerative Medicine Support Business and its Cell Sheet Regenerative Medicine Business.

The biggest news in 2025 was the start of the clinical trial of the allogeneic chondrocyte sheet (CLS2901C). The first patient was enrolled in the Phase III clinical trial on October 9, 2025, and the trial is progressing as planned. We also added new clinical sites and updated trial information, steadily advancing the development program.

In the Cell Cultureware Business, we enhanced collaboration with existing domestic distributors and conducted information gathering and promotional activities by exhibiting at major academic conferences, including the Japanese Society for Regenerative Medicine, the Pharmaceutical Society of Japan, the Japanese Society of Toxicology, and the Japanese Society for Alternatives to Animal Experiments. In overseas markets where the major part of the revenue comes from, sales declined significantly due to budget cuts at U.S. research institutions and geopolitical disruptions in Europe and the Middle East. We will continue to monitor market trends while pursuing the expansion of existing product sales and the development of new products.

In the Regenerative Medicine Contract Service Business, we supported the procedures necessary for the start of private-practice treatment at Tokyo Metropolitan Tama-Hokubu Medical Center. In addition, we entered into a technical disclosure agreement with NPT Co., Ltd. regarding the clinical trial manufacturing of its personalized dendritic cell vaccine. Through proactive communication of our activities as a Contract Development and Manufacturing Organization (CDMO), we will continue working to secure new contract projects.

The 4th Cell Sheet Engineering Innovation Forum, held in November 2025, welcomed more than 100 external participants and concluded successfully. The quality of presentations has improved with each event, and we believe that enhanced interaction within the research community will further advance the field of cell sheet engineering and accelerate its social implementation.

This year marks the 25th anniversary of CellSeed Inc.. On this important milestone, we remain committed to strengthening our research, development, and commercialization efforts to realize regenerative medicine based on cell sheet engineering.
We appreciate your continued support to our business.